SectorPharmaceuticals & Healthcare
- Alkem Laboratories Limited
- Dishman Carbogen Amcis Limited
- Gaudium IVF and Women Health Limited
- Gufic Biosciences Limited
- Ind-Swift Laboratories Limited
- IOL Chemicals & Pharmaceuticals Ltd
- IPCA Laboratories Limited
- Krsnaa Diagnostics Limited
- Laxmi Dental Limited
- Manipal Health Enterprises Limited
- Marksans Pharma Limited
- Max Healthcare Institute Limited
- Natco Pharma Limited
- Nephrocare Health Services Limited
- QMS Medical Allied Services Limited
- Rubicon Research Limited
- Shaily Engineering Plastics Limited
- Shalby Limited
- Viyash Scientific Limited
- Yatharth Hospital & Trauma Care Services Limited
- Zota Health Care LImited
- Zydus Lifesciences Limited
Manipal Hospitals delivered strong growth in its first quarter as a public company, driven by patient demand, high-acuity specialty care, and the integration of Sahyadri Hospitals.
Max Healthcare posted strong revenue growth and continued its capacity expansion while embarking on a new medical education business.
The company delivered strong financial performance driven by its transformation into a focused FDF manufacturer, with new CDMO partnerships commercialized and sharp margin expansion.
Zydus Lifesciences started FY27 with strong double-digit growth across all key businesses, driven by branded formulations in India, international markets, and strategic advancements in specialty and innovation.
Gufic Biosciences delivered strong Q1 growth driven by improved margins from its new Indore plant, progress on complex injectable capabilities, and a strategic shift in its international business model.
Despite a soft revenue quarter, management is focused on sales force expansion, tech transfers to India, and a significant debt refinancing to improve margins, projecting an optimistic future.
Q1 FY27 saw strong revenue and profit growth driven by scaling service business (Patient Support Programs) and strategic investments beginning to yield results.
Strong profit growth driven by a bumper flu season in the associate Adcock Ingram and double-digit growth in the base business.
Ipca delivered robust 21% revenue growth and significantly improved EBITDA margins by 4.49 percentage points to 22.88%, revising its full-year revenue growth guidance upward.
Revenue growth was driven by international sales and branded formulations in India, but net profit declined sharply due to tax impacts and ongoing investments in new, loss-making CDMO and MedTech businesses.
The company began FY27 with strong momentum, driven by retail network expansion and increased consumer footfalls, while planning a moderated pace of store openings to focus on productivity.
The quarter was driven by the transition of the large Rajasthan PPP project from infrastructure build-out to revenue generation, strong retail growth, and a new project win in Himachal Pradesh.
Gaudium IVF's Q1 focused on investing ahead of its expansion roadmap, absorbing higher costs for marketing its new AI tools and new hub development while maintaining confidence in achieving its full-year growth targets.
Rubicon delivered strong top-line and bottom-line growth, raised EBITDA guidance, and advanced its strategic manufacturing footprint with a new U.S. site.
Strong Q1 growth driven by successful diversification beyond ibuprofen, with non-ibu APIs contributing 43% of pharma revenue and a 60.7% EBITDA increase.
The company started FY27 with record quarterly revenue, EBITDA, and PAT, driven by strong European growth via acquisitions and organic expansion across all geographies.
The quarter was about the hospital segment showing steady revenue growth while MedTech delivered strong top-line expansion, but both faced profitability pressure and management is focused on executing levers for margin improvement.
NephroPlus delivered strong Q1 growth with revenue up 23.7% and continued strategic expansion into new cities and countries, driven by its scalable platform model focused on quality, accessibility, and affordability of dialysis care.
Laxmi Dental achieved its highest-ever quarterly revenue and profitability, driven by strong growth across its dental lab and aligner solutions businesses.
Viyash delivered strong Q1 growth with improved margins and a strengthened, nearly debt-free balance sheet, positioning it for strategic investments in R&D, manufacturing, and targeted M&A.
Yatharth delivered its highest ever quarterly revenue and profits, with 51% revenue growth driven by successful integration and rapid scaling of newer hospitals, while maintaining a focus on premium payer mix and expansion to 5,000 beds.
Healthcare, now the largest segment with 85% revenue growth, drove overall performance amid a challenging global environment and softer Consumer demand.